

References

I-222

1. American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. *Headache*. 2019; 59(1):1-18
2. Deng H, Li G, Nie H, et al. Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis. *BMC Neurology*. 2020;20(1):1-12
3. Ashina M, Saper J, Cady R, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). *Cephalalgia*. 2020. 40(3):241-254
4. Vyepiti (eptinezumab-jjmr) injection, for intravenous use [package insert]. Lundbeck Seattle BioPharmaceuticals, Inc. Bothell, WA. Revised 02/2020
5. Clinical Pharmacology Compendia [database online]. Tampa FL: Gold Standard, Inc. Eptinezumab. 2020
6. Micromedex® Solutions Compendia. 2020. Eptinezumab
7. MCG™ Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).